Pfizer Inc. (NYSE: PFE) Finds That Paxlovid Cannot Prevent COVID-19 Infection

Pfizer Inc. (NYSE: PFE) has found that its Paxlovid pill might not effectively prevent COVID-19 in people who have come in contact with infected individuals. Paxlovid is an oral drug which the Food and Drug Administration (FDA) approved for the treatment of COVID-19.

In the study, the company gave the pill to people for five and ten days, respectively. Researchers saw a 32% and 37% risk reduction rate in the volunteers. However, this figure was not statistically significant. As a result, the company concluded that the drug didn’t reduce the likelihood of contracting COVID-19 for people who shared a household with an infected person.

Pfizer states that these disappointing results do not impact the drug’s efficacy in treating the disease.

Reports indicate rebounding virus levels after taking Paxlovid

However, the analysts believe this news won’t change the drug’s sales. There have also been reports of rebounding virus levels after patients finish a course of the drug. While this was initially rare, there have been an increasing number of cases. Scientists are now investigating what could be causing the relapse.

Pfizer has stated that it takes the news seriously and will be investigating the claims. Paxlovid has been proven to reduce the rates of hospitalisation and death. For this reason, many believe that the risk of testing positive for a second time should not outweigh the benefits the oral pill has had during this pandemic. Moreover, the claims of relapse are mostly anecdotal.

Pfizer is expected to release its financial results for Q1 2022. Analysts anticipate that the company could fall short of estimates. However, it could also make high revenue from Inlyta and Ibrance, two cancer drugs.

Poland invoked a force majeure clause 

Adam Niedzielski, the health minister of Poland, revealed that Warsaw had told Pfizer and the European Commission that it wouldn’t pay for or take COVID-19 vaccines from the company. After this, Poland invoked a force Majeure clause in its Pfizer contract. This decision came after an increase in Ukrainian refugees in the country. The European Commission has stated that there was no need to invoke the clause as Ukraine hadn’t changed their vaccination needs.

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at

Published by Benjamin Roussey

Benjamin Roussey is from Sacramento, California. He has two master’s degrees and served four years in the U.S. Navy. His bachelor’s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master’s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing.